Which one is better: brigatinib/brigatinib or lorlatinib?

Brigatinib and Lorlatinib are well-known tyrosine kinase inhibitors used to treat non-small cell lung cancer (NSCLC) with specific genetic alterations, mainly ALK-positive tumors. Brigatinibis often used after failure of crizotinib and has shown high efficacy in inhibiting ALK mutations, including some that are resistant to first-line therapy. In contrast, lorlatinib is a third-generation ALK inhibitor that can be used after other ALK inhibitors have failed and is known for its ability to penetrate the blood-brain barrier, potentially more effectively treating or preventing brain metastases. When deciding between the two, the key is to consider the tumor's specific mutational signature, previous treatments and potential side effects of each drug, and to use the drugs under a physician's guidance.

Brigatinib is an anaplastic lymphoma kinase (ALK) inhibitor approved for the treatment of patients with ALK-positive metastatic non-small cell lung cancer who have progressed on or are intolerant to crizotinib. Clinical trials have shown that brigatinib has significant efficacy in this patient population. In the pivotal Phase 2 trial known as ALTA, patients treated with brigatinib after failure of crizotinib had an objective response rate (ORR) of 45-56%, depending on the dose received. Additionally, median progression-free survival (PFS) was reported to be between 13.8 and 16.7 months, highlighting the drug's potential in controlling disease progression. Further supporting its efficacy, brigatinib showed activity against central nervous system (CNS) metastasis, a common complication of ALK-positive non-small cell lung cancer. In the ALTA trial, intracranial response rates were encouraging, with a significant proportion of patients experiencing reduction in central nervous system lesions. This ability to penetrate the blood-brain barrier and exert anti-tumor effects within the central nervous system is a significant advantage in the treatment of brain metastases from lung cancer.

Lorlatinib is another ALK inhibitor used to treat ALK-positive metastatic non-small cell lung cancer. It is designed to inhibit the most common ALK mutations, including those that are resistant to other ALK inhibitors. Lorlatinib is particularly effective in patients who have previously received one or more ALK inhibitors. In a phase 2 trial, lorlatinib had an ORR of 47% in patients who had received at least one ALK inhibitor. Median PFS was impressive, with patients experiencing a median duration of 7.0 months before disease progression. Similar to Bugatinib, lorlatinib has also shown strong ability to control central nervous system metastasis in patients with ALK-positive non-small cell lung cancer. In clinical studies, lorlatinib achieved significant intracranial responses, demonstrating its effectiveness in treating and controlling brain metastases. This feature is particularly valuable because central nervous system involvement is a challenging aspect of lung cancer treatment and is associated with poor prognosis. Lorlatinib's ability to address this issue provides a critical option for patients with advanced disease.